Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

9 Customer Reviews

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

    Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

  • Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

    The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MnW4T4lv[XOnIFHzd4F6 MVLJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER|M4KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1? MVuyOFkxODZ5Mx?=
SK-MEL-28 MXTLbY5ie2ViQYPzZZk> MmHHNUBp MYXJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh|ryP NWTO[4RGOjR7MEC2O|M>
HepG2 M2LCNWtqdmG|ZTDBd5NigQ>? M{P6VGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFXST{BxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC0JO69VQ>? Mme4NlQ6ODB4N{O=
COLO205 NEK2SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2wR2UzUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPNlA2KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xODdizszN NFHQZm8zPDlyME[3Ny=>
HepG2 MYHGeY5kfGmxbjDBd5NigQ>? MYq0OUBucW5? NGjueFJFVVOR NVj6VpA5UW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=> MXGyOFkxODZ5Mx?=
HFF M4fLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TrWFExKM7:TR?= NVf1NnpKPzJiaB?= NHPKNHZFVVOR NH;m[|NKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR|UxKG:oIEOg{txO MUOyN|g1PDB|OB?=
SK-MEL-28 M{e1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P5PVExKM7:TR?= NWj2TFZ1PzJiaB?= MVrEUXNQ M3LmdmlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0> NXuyfGp[OjN6NESwN|g>
A375P-F11 NH;5O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHINVAh|ryP NHHnO204OiCq NWXhc2x{TE2VTx?= MlTyTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=> NXHjb2JYOjN6NESwN|g>
MALME-3M MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULaTZF4OTBizszN M{XL[FczKGh? NHPNNYRFVVOR NVvlXWJWUUN3ME2xJI5O NWPpZ2Q5OjN6NESwN|g>
UACC-62 NHnNNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2Onc1OTBizszN NF63NIM4OiCq MYXEUXNQ MkPtTWM2OD1zIH7N M2Hac|I{QDR2MEO4
C32TG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? NYWyOnBoPzJiaB?= Mof0SG1UVw>? M3\afWlEPTB;MTDuUS=> NUfwfpZQOjN6NESwN|g>
SK-MEL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP5cIcyOCEQvF2= M4ThPFczKGh? M1nkS2ROW09? MlHmTWM2OD1{IH7N M{GyblI{QDR2MEO4
M14 NYLu[|dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxNEDPxE1? M3y0TFczKGh? MXTEUXNQ M1XxbWlEPTB;MjDuUS=> NGSzZWYzOzh2NECzPC=>
SK-MEL-28 NYj6NlVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fxdlExKM7:TR?= NGrBV2U4OiCq M1vBU2ROW09? NILzbYpKSzVyPUOgcm0> NGDLbGwzOzh2NECzPC=>
A375 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WydFExKM7:TR?= MXK3NkBp NWLER3czTE2VTx?= NVPhZXRxUUN3ME20JI5O NXTld|R2OjN6NESwN|g>
DU-4475 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXLdFhEOTBizszN M1zEfVczKGh? NG\teGZFVVOR NUHFb3V4UUN3ME21JI5O NXG3b5hSOjN6NESwN|g>
UACC-257 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLTUXAyOCEQvF2= NWHBRmMxPzJiaB?= NX;pVJRpTE2VTx?= MXjJR|UxRTZibl2= NEXMUXQzOzh2NECzPC=>
Colo 205 M3POdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XiTFExKM7:TR?= M1\tUVczKGh? MoXiSG1UVw>? MYHJR|UxRTdibl2= MmHDNlM5PDRyM{i=
SK-MEL-3 NEniZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnERXg2OTBizszN MXe3NkBp M3i2[2ROW09? MX3JR|UxRTdibl2= MV[yN|g1PDB|OB?=
SH-4 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfRSHMyOCEQvF2= MlvVO|IhcA>? MmTuSG1UVw>? M4jFcGlEPTB;ODDuUS=> NGO3eXozOzh2NECzPC=>
A101D NHLOZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfSVW0yOCEQvF2= NEXud2o4OiCq MnPISG1UVw>? NWPQbWVEUUN3ME25JI5O M1rwWVI{QDR2MEO4
ES-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rlU|ExKM7:TR?= MlzZO|IhcA>? Mn\vSG1UVw>? M4Xa[mlEPTB;NUOgcm0> M2P1eVI{QDR2MEO4
HT-29 NWLUb4J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITuPXoyOCEQvF2= NEDvdIU4OiCq MmPiSG1UVw>? NFvGcZBKSzVyPU[2JI5O MWCyN|g1PDB|OB?=
SW1417 NXLkdHoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDaVocyOCEQvF2= M4izZ|czKGh? M2\ocmROW09? NWWyem84UUN3ME2xOVghdk1? MWqyN|g1PDB|OB?=
SW872 M3m0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DXN|ExKM7:TR?= M3;VdFczKGh? MWTEUXNQ MnHWTWM2OD1|N{egcm0> NUjQc2VuOjN6NESwN|g>
RKO M{nZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LnUVExKM7:TR?= NV30XGV7PzJiaB?= NVjDe3RkTE2VTx?= NF\vZphKSzVyPUKuOVIzKM7:TR?= NHewb4QzOzh2NECzPC=>
A673 NYHNOHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H0fVExKM7:TR?= MXe3NkBp NX;0cFhGTE2VTx?= NXOwT4NJUUN3ME2xNEDPxE1? NIHJUIYzOzh2NECzPC=>
GCT NEjYe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILISoEyOCEQvF2= M3;SOlczKGh? NHLRcGdFVVOR NVjDOHh{UUN3ME2xNEDPxE1? NGq5NFUzOzh2NECzPC=>
WM-115 M1XnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13kclExKM7:TR?= MWq3NkBp NFTWTI9FVVOR NHm0dppKSzVyPUWgcm0> NHHR[|czOzh2NECzPC=>
YUMAC NHr4[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xNEDPxE1? M1rSU|czKGh? MW\EUXNQ MoDzTWM2OD13IH7N NYPPVW9qOjN6NESwN|g>
OV-90 NFjXOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiwU|M3OTBizszN MUC3NkBp MV7EUXNQ NEXPeZhKSzVyPUK5JI5O M4rydFI{QDR2MEO4
NCI-H508 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzZ[VgyOCEQvF2= NF\JNoY4OiCq NGPMW|lFVVOR MnnsTWM2OD1zMDFOwG0> MUCyN|g1PDB|OB?=
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? Mo\wO|IhcA>? NUDaNIxZTE2VTx?= NYflNWQ2UUN3ME2xNEDPxE1? MVKyN|g1PDB|OB?=
SW756 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Cze|ExKM7:TR?= MYe3NkBp NELkZYtFVVOR MYDJR|UxRTFyIN88US=> Mn3CNlM5PDRyM{i=
SW-837 NIr1SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrMSG46OTBizszN MmDkO|IhcA>? MWXEUXNQ Mnj5TWM2OD1zMDFOwG0> M{PLNFI{QDR2MEO4
UMUC-3 NUTx[4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixNEDPxE1? MmTuO|IhcA>? M2Tic2ROW09? NIL0XlZKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
LS-174T MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTRXmpJOTBizszN MlXoO|IhcA>? MmC0SG1UVw>? Mn7FTWM2OD1zMDFOwG0> Mlv3NlM5PDRyM{i=
A549 NYPDd5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X5PFExKM7:TR?= NHz4WVE4OiCq M1nhb2ROW09? M{DX[2lEPTB;MUCg{txO NXLENZlEOjN6NESwN|g>
SHP-77 NGnOcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxNEDPxE1? MYC3NkBp MV7EUXNQ M2nZN2lEPTB;MUCg{txO NGiycGQzOzh2NECzPC=>
SW480 NVvDO|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHxNVAh|ryP NGXke|Y4OiCq NW[wXJBVTE2VTx?= NX7mUVM3UUN3ME2xNEDPxE1? M3jENlI{QDR2MEO4
DLD-1 NYDF[|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0UYtDOTBizszN NX;2fplNPzJiaB?= MkLXSG1UVw>? NV;x[YM6UUN3ME2xNEDPxE1? NHXTWXMzOzh2NECzPC=>
HCT-116 M4f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzlNVAh|ryP NX3scpdIPzJiaB?= NXLVZmRpTE2VTx?= MXXJR|UxRTFyIN88US=> NEC5PJkzOzh2NECzPC=>
NCI-H747 NUK3d205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNEDPxE1? MWi3NkBp MYTEUXNQ MXPJR|UxRTFyIN88US=> NF:4OYczOzh2NECzPC=>
T-84 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\INVAh|ryP MlrtO|IhcA>? MWrEUXNQ NE\UUm9KSzVyPUGwJO69VQ>? MXOyN|g1PDB|OB?=
NCI-H460 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xNEDPxE1? NVXDPXZwPzJiaB?= MkPYSG1UVw>? M3XmeWlEPTB;MUCg{txO NEPOeWszOzh2NECzPC=>
Calu-6 M1exNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXzNVAh|ryP Mn;tO|IhcA>? MVfEUXNQ MXXJR|UxRTFyIN88US=> NIHR[FYzOzh2NECzPC=>
HCC-2998 NXr4e41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGfVExKM7:TR?= MUK3NkBp NHXMfo1FVVOR NGHQPYlKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
LS1034 NHvJPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDoUVYyOCEQvF2= MoXBO|IhcA>? M3jUR2ROW09? MkmxTWM2OD1zMDFOwG0> MmDZNlM5PDRyM{i=
CHP-212 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNEDPxE1? NUXTcGJJPzJiaB?= NXr4Rm5JTE2VTx?= Mn7mTWM2OD1zMDFOwG0> MXWyN|g1PDB|OB?=
SK-N-AS NEfyUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHWNVAh|ryP Mn3PO|IhcA>? MWTEUXNQ NVvKUpA6UUN3ME2xNEDPxE1? NX62cY1oOjN6NESwN|g>
BFTC-905 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfCNVAh|ryP NIOxdnk4OiCq MWrEUXNQ NWP4[mZ2UUN3ME2xNEDPxE1? Ml;iNlM5PDRyM{i=
HuT78 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLzNVAh|ryP M2[3b|czKGh? M4r5fGROW09? Mn3YTWM2OD13MjDuUS=> M4\aNFI{QDR2MEO4
RPMI-8226 NVq3[3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxNEDPxE1? MnvpO|IhcA>? Mn\mSG1UVw>? NXTuO2pbUUN3ME2yOlMhdk1? NI\xWpYzOzh2NECzPC=>
BC-3 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\TNVAh|ryP MlzNO|IhcA>? NFG0W4ZFVVOR M2DlXWlEPTB;Mke3JI5O Mnf0NlM5PDRyM{i=
ACHN NYLaVm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuy[YIyOCEQvF2= NUPxc3J{PzJiaB?= NVj1cGx{TE2VTx?= MUfJR|UxRTJ7NDDuUS=> MoK3NlM5PDRyM{i=
JRT3-T35 M3;xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr3RXE3OTBizszN NVm5TGhGPzJiaB?= M4rMWWROW09? NWnZWZZ[UUN3ME2yPVUhdk1? NHHsXGQzOzh2NECzPC=>
SK-MES-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxNEDPxE1? M{D6S|czKGh? MWDEUXNQ MWXJR|UxRTN{OTDuUS=> NHXoOlQzOzh2NECzPC=>
CESS M4nEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLmNVAh|ryP NWT5Uo9IPzJiaB?= MVjEUXNQ MULJR|UxRTR7NzDuUS=> MnfRNlM5PDRyM{i=
H4 M1v0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWcIM1OTBizszN NV\RfnJMPzJiaB?= MknrSG1UVw>? NGDU[pJKSzVyPU[xPUBvVQ>? NVzQUohxOjN6NESwN|g>
BC-1 NWHJcYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TufFExKM7:TR?= MYC3NkBp Mlf6SG1UVw>? NWLBe5dSUUN3ME23NFQhdk1? M4XtWlI{QDR2MEO4
DB NGDiNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W3dVExKM7:TR?= MWq3NkBp NIfTfHZFVVOR M4DOR2lEPTB;OEezJI5O NFrOe3gzOzh2NECzPC=>
RPMI-6666 NUO1dHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjweWIyOCEQvF2= M1mzUFczKGh? NIPVU|ZFVVOR M{L2UmlEPTB;OUK4JI5O NI\hRVAzOzh2NECzPC=>
MC/CAR NUW1N2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TZblExKM7:TR?= MWq3NkBp MVzEUXNQ MnTxTWM2OD1zLkCwNkDPxE1? NWO5OWwyOjN6NESwN|g>
SNU-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xNEDPxE1? NITzW5A4OiCq NULpe2U2TE2VTx?= MXLJR|UxRTFwNUCxJO69VQ>? MXeyN|g1PDB|OB?=
CEM/C1 M4TjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXiSJljOTBizszN MYi3NkBp NYO2eWFkTE2VTx?= MXzJR|UxRTFwN{ezJO69VQ>? NInKVowzOzh2NECzPC=>
GDM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XLWFExKM7:TR?= M{m0eFczKGh? M3\QUmROW09? M3PQOGlEPTB;MT65PVch|ryP MnnrNlM5PDRyM{i=
HT-1080 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[xSmIyOCEQvF2= Mk\CO|IhcA>? MWHEUXNQ NULXemdHUUN3ME2yMlAxPCEQvF2= Mnu5NlM5PDRyM{i=
HL-60 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[0O2MyOCEQvF2= M4Xqb|czKGh? MWXEUXNQ M1nKTGlEPTB;Mj6xO|gh|ryP MlHMNlM5PDRyM{i=
C3A NF;IWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNEDPxE1? NYfaTFJHPzJiaB?= Mk\xSG1UVw>? MX\JR|UxRTVwNEG0JO69VQ>? NIrXS5EzOzh2NECzPC=>
MES-SA M3vjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH2T|IyOCEQvF2= MVO3NkBp MWLEUXNQ MmHnTWM2OD14Lkm4PUDPxE1? MmHVNlM5PDRyM{i=
22Rv1 NEXyWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K2O|ExKM7:TR?= NFTzemY4OiCq NIjDRo1FVVOR NULEeXNvUUN3ME2xNEDPxE1? M2DaZlI{QDR2MEO4
647-V NFW1PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXpb3cyOCEQvF2= MkXIO|IhcA>? NE\vWW1FVVOR NX:zNHN3UUN3ME2xNEDPxE1? M3jMVFI{QDR2MEO4
786-O NX;lVnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXsNVAh|ryP Mnr3O|IhcA>? M4r5UWROW09? MYXJR|UxRTFyIN88US=> MUmyN|g1PDB|OB?=
A172 NYf6U29lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2SFExKM7:TR?= NWLX[mxqPzJiaB?= NFjXUmxFVVOR MUTJR|UxRTFyIN88US=> NILy[oYzOzh2NECzPC=>
A204 M33nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxNEDPxE1? M2raOlczKGh? M2mxVWROW09? NYLKb3B7UUN3ME2xNEDPxE1? NY[yTJZbOjN6NESwN|g>
A427 M{DZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqxNEDPxE1? MYG3NkBp NWXhSVBpTE2VTx?= M4rCUmlEPTB;MUCg{txO MXSyN|g1PDB|OB?=
A431 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxNEDPxE1? NVLEVnR5PzJiaB?= M4DvVWROW09? MUfJR|UxRTFyIN88US=> MXqyN|g1PDB|OB?=
A2780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPOOmNUOTBizszN Ml[2O|IhcA>? M1fYRmROW09? MnrDTWM2OD1zMDFOwG0> NYrZRopjOjN6NESwN|g>
ARH-77 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? NX73b3VGPzJiaB?= NE[wcZpFVVOR NVLpOVNbUUN3ME2xNEDPxE1? MX[yN|g1PDB|OB?=
Be(2)C NVnjS29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TIdFExKM7:TR?= MUe3NkBp M3nHXmROW09? M3PuXmlEPTB;MUCg{txO MXqyN|g1PDB|OB?=
BT-20 NFvJb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP4Wm4yOCEQvF2= NXjsNIYzPzJiaB?= NWXlb2VITE2VTx?= MU\JR|UxRTFyIN88US=> NFvXcYYzOzh2NECzPC=>
BxPc3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX0SZUyOCEQvF2= NEPHVYc4OiCq MVjEUXNQ MWPJR|UxRTFyIN88US=> MVOyN|g1PDB|OB?=
C-4 I NFuyfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXIWWFzOTBizszN M1LiVFczKGh? MXTEUXNQ NXnrSXZ3UUN3ME2xNEDPxE1? NEPn[nAzOzh2NECzPC=>
C33A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOyN2lxOTBizszN NETwelg4OiCq MXnEUXNQ M1zLcWlEPTB;MUCg{txO MofLNlM5PDRyM{i=
CAL-27 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;CV|cyOCEQvF2= MkfiO|IhcA>? NHzTTZFFVVOR MV\JR|UxRTFyIN88US=> MonYNlM5PDRyM{i=
CAL-62 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNEDPxE1? NYKyOph6PzJiaB?= NVL1[JpQTE2VTx?= MlSzTWM2OD1zMDFOwG0> MkLNNlM5PDRyM{i=
Calu-3 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rPXlExKM7:TR?= M{DydlczKGh? NELJXXZFVVOR M1LZT2lEPTB;MUCg{txO M1zR[|I{QDR2MEO4
CaOV3 M{HPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjjbVEyOCEQvF2= NFjWUFk4OiCq NGfHcnRFVVOR NV7aZ|c1UUN3ME2xNEDPxE1? MWmyN|g1PDB|OB?=
CGTHW1 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jDXlExKM7:TR?= Mk\5O|IhcA>? NUfHcoFtTE2VTx?= MnLZTWM2OD1zMDFOwG0> MlfNNlM5PDRyM{i=
CHL-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PC[|ExKM7:TR?= MVK3NkBp NF3M[IZFVVOR MXzJR|UxRTFyIN88US=> M2jSe|I{QDR2MEO4
Colo320DM NYj3OWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyzVJYyOCEQvF2= M4raPFczKGh? NGLpcWFFVVOR NH7CeVdKSzVyPUGwJO69VQ>? NFzWdW8zOzh2NECzPC=>
Colo704 NGrNdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTTNVAh|ryP M{T0UlczKGh? MXPEUXNQ NGPLPWdKSzVyPUGwJO69VQ>? M{OwTVI{QDR2MEO4
COR-L23 NFXXN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGxNEDPxE1? NH\wPY84OiCq MV;EUXNQ NXfhUG8xUUN3ME2xNEDPxE1? Mmi1NlM5PDRyM{i=
CRO-AP2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjPfVA1OTBizszN M1O3fVczKGh? NIDLNHJFVVOR NGPJeJFKSzVyPUGwJO69VQ>? NFnxN3kzOzh2NECzPC=>
Daudi NEfRemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorENVAh|ryP NWDCeFA3PzJiaB?= Mn;pSG1UVw>? MmDnTWM2OD1zMDFOwG0> NYPGTnh5OjN6NESwN|g>
DOTC 24510 M4\N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? MlXKO|IhcA>? MlrnSG1UVw>? Mne5TWM2OD1zMDFOwG0> MofHNlM5PDRyM{i=
DU-145 NIe5[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVyxUHR[OTBizszN NGSwepk4OiCq MkGySG1UVw>? M3HE[GlEPTB;MUCg{txO M1rpb|I{QDR2MEO4
EB-3 NYXqUVByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq5Uo5bOTBizszN NULyZ4YyPzJiaB?= MmjySG1UVw>? NVfOW5hjUUN3ME2xNEDPxE1? NEDkeXczOzh2NECzPC=>
EFM-19 NV\BNJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7rd2wyOCEQvF2= MVO3NkBp NI\PSINFVVOR NI\rSnNKSzVyPUGwJO69VQ>? M1HnWlI{QDR2MEO4
EKVX NELte3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLtS4R{OTBizszN NEfwOIw4OiCq M2nhcWROW09? NUL6WZJ7UUN3ME2xNEDPxE1? Mk\XNlM5PDRyM{i=
FaDu MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\kNVAh|ryP MVS3NkBp MlrXSG1UVw>? NXXNfGtIUUN3ME2xNEDPxE1? M4DNVFI{QDR2MEO4
G401 NHHtUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4foXVExKM7:TR?= MoDrO|IhcA>? MXrEUXNQ NHH1UFdKSzVyPUGwJO69VQ>? NYDqelNVOjN6NESwN|g>
HCC-70 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPofWgyOCEQvF2= NGPOVmE4OiCq NW\Pd4xSTE2VTx?= M4XyNGlEPTB;MUCg{txO MVyyN|g1PDB|OB?=
HCC-1954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO2NVAh|ryP NWf5cWdQPzJiaB?= NIXpS4VFVVOR MUfJR|UxRTFyIN88US=> MXSyN|g1PDB|OB?=
Hela NXvENWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jmXlExKM7:TR?= MnjzO|IhcA>? MmTjSG1UVw>? M{DZOWlEPTB;MUCg{txO NWXLWnQ1OjN6NESwN|g>
Hep3B MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? MoXDO|IhcA>? NHK1TlNFVVOR Mk\pTWM2OD1zMDFOwG0> NXjCd2RGOjN6NESwN|g>
HMCB NGDpUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNEDPxE1? NFXHXHk4OiCq MY\EUXNQ NGjGcGJKSzVyPUGwJO69VQ>? Mo\uNlM5PDRyM{i=
HN5 NHLVd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzaOFYyOCEQvF2= Ml;hO|IhcA>? Ml7GSG1UVw>? NX7CZ5JGUUN3ME2xNEDPxE1? M{XadlI{QDR2MEO4
HOS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vL[lExKM7:TR?= M{Dk[|czKGh? M13mdmROW09? MkXETWM2OD1zMDFOwG0> MkDjNlM5PDRyM{i=
HPAF-II MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfMNoFtOTBizszN MVe3NkBp MojpSG1UVw>? M3Xke2lEPTB;MUCg{txO MkDzNlM5PDRyM{i=
Hs746.T NFLtPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL4NVAh|ryP MV:3NkBp MnTySG1UVw>? M17pcWlEPTB;MUCg{txO MUGyN|g1PDB|OB?=
HT M{H0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? NIrme4g4OiCq MkTaSG1UVw>? NXXoSo5TUUN3ME2xNEDPxE1? MXSyN|g1PDB|OB?=
HT-3 NUDSS25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXoNVAh|ryP MWO3NkBp M4rkeGROW09? M4X5UWlEPTB;MUCg{txO MmGwNlM5PDRyM{i=
HuNS-1 NWfIdXJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxNEDPxE1? NIfuWXE4OiCq NVXadlZITE2VTx?= NH;NcZlKSzVyPUGwJO69VQ>? NHnSOoYzOzh2NECzPC=>
IGROV1 NEfITJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPMNVAh|ryP NFvXW3E4OiCq NHXHV3FFVVOR NETYfJlKSzVyPUGwJO69VQ>? NVzONlFGOjN6NESwN|g>
J82 NGfrb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv0NVAh|ryP NHfKXI04OiCq NHHBPJRFVVOR NFHQSHBKSzVyPUGwJO69VQ>? MXOyN|g1PDB|OB?=
JM1 NHjVRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzSR4pnOTBizszN M{HMclczKGh? NWrGXWw{TE2VTx?= M1\PNGlEPTB;MUCg{txO NULP[YUyOjN6NESwN|g>
Kato III NF3GdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNEDPxE1? NGW4R5A4OiCq Mly1SG1UVw>? NHvVV45KSzVyPUGwJO69VQ>? NX\zTVIxOjN6NESwN|g>
KHOS-240S MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjtNVAh|ryP NETNOoo4OiCq NY\NVmZFTE2VTx?= NUG0VYtyUUN3ME2xNEDPxE1? MUSyN|g1PDB|OB?=
KM-12 NVribnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfKPZB{OTBizszN NWTsXG1EPzJiaB?= NFjMeIdFVVOR MYLJR|UxRTFyIN88US=> NFnocoUzOzh2NECzPC=>
KPL-1 M1TZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNEDPxE1? MV[3NkBp M3HtW2ROW09? M{XyOGlEPTB;MUCg{txO Mn3ENlM5PDRyM{i=
KYSE-30 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? MnnVO|IhcA>? MmXaSG1UVw>? MWTJR|UxRTFyIN88US=> NIP0SoQzOzh2NECzPC=>
LNCaP MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJXlExKM7:TR?= M2fWPVczKGh? NHrhN5JFVVOR MkfrTWM2OD1zMDFOwG0> Mn\0NlM5PDRyM{i=
MCF-7 NXWxPZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;WNVAh|ryP NF:xZ4w4OiCq MVHEUXNQ MnyzTWM2OD1zMDFOwG0> MonnNlM5PDRyM{i=
MC-IXC Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T5TFExKM7:TR?= M2O5PFczKGh? NGexOlhFVVOR NHW4cXZKSzVyPUGwJO69VQ>? MkGyNlM5PDRyM{i=
MDA-MB-175 VII NXi0NnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln1NVAh|ryP NITaVIw4OiCq Mo\zSG1UVw>? MYXJR|UxRTFyIN88US=> NYPS[G5nOjN6NESwN|g>
MDA-MB-468 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPpNJAyOCEQvF2= M2ewcFczKGh? NH6yZ2pFVVOR MWjJR|UxRTFyIN88US=> M3;vRlI{QDR2MEO4
MiaPaCa M4HxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnLZZBuOTBizszN MX63NkBp MkTSSG1UVw>? NWPvcYJoUUN3ME2xNEDPxE1? Mlu1NlM5PDRyM{i=
Molt-4 NUjwPYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKyNVAh|ryP MmnBO|IhcA>? NFvVdW1FVVOR M3Hr[2lEPTB;MUCg{txO M3nvXVI{QDR2MEO4
NCI-ADR/RES NVrQNlRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmryNVAh|ryP MorQO|IhcA>? MmTvSG1UVw>? M1LRNWlEPTB;MUCg{txO NUHuSFNQOjN6NESwN|g>
NCI-H69 M2\BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLkVoUyOCEQvF2= NYDFO3NXPzJiaB?= M1riV2ROW09? Ml3zTWM2OD1zMDFOwG0> M33pUFI{QDR2MEO4
NCI-H82 NWHNeVcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\pOpV4OTBizszN MXK3NkBp MXjEUXNQ MVvJR|UxRTFyIN88US=> M{\ucFI{QDR2MEO4
NCI-N87 M{THcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W3eFExKM7:TR?= NWTRe4loPzJiaB?= NV;5TYEyTE2VTx?= MXfJR|UxRTFyIN88US=> NYOwfZl1OjN6NESwN|g>
NCI-H146 NV;NSW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNEDPxE1? M3Hv[VczKGh? M4j6W2ROW09? MmXQTWM2OD1zMDFOwG0> NXz4UpV4OjN6NESwN|g>
NCI-H157 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? MkHPO|IhcA>? NXG1NFBSTE2VTx?= NYrlSmFxUUN3ME2xNEDPxE1? NYr0UHdKOjN6NESwN|g>
NCI-H187 NWfBWHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;I[|ExKM7:TR?= NGnjUXY4OiCq MXrEUXNQ M4O1dGlEPTB;MUCg{txO M1z1fVI{QDR2MEO4
NCI-H209 M1;LS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxNEDPxE1? NVvte5BqPzJiaB?= M4jRN2ROW09? MWXJR|UxRTFyIN88US=> MVSyN|g1PDB|OB?=
NCI-H226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml36NVAh|ryP Mn3SO|IhcA>? MXTEUXNQ MWXJR|UxRTFyIN88US=> M17VNFI{QDR2MEO4
NCI-H292 NXW4UoRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vNVAh|ryP M33zO|czKGh? NIjPfGNFVVOR MoLHTWM2OD1zMDFOwG0> NEiwXW4zOzh2NECzPC=>
NCI-H322 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxNEDPxE1? NVHsPHhSPzJiaB?= NFL2bIZFVVOR M{i4UGlEPTB;MUCg{txO NVi4T2J3OjN6NESwN|g>
NCI-H358 NGHHPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnIV3c2OTBizszN Mkf6O|IhcA>? M{nhTGROW09? NVrje2VqUUN3ME2xNEDPxE1? MVeyN|g1PDB|OB?=
NCI-H520 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[2OlExKM7:TR?= MYW3NkBp MoTBSG1UVw>? MmOzTWM2OD1zMDFOwG0> MUeyN|g1PDB|OB?=
NCI-H526 M4nLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqd|MyOCEQvF2= MXK3NkBp Ml:zSG1UVw>? NUTiToZIUUN3ME2xNEDPxE1? NInYbFgzOzh2NECzPC=>
NCI-H630 M{DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQeItQOTBizszN Mnq4O|IhcA>? MVjEUXNQ Ml\aTWM2OD1zMDFOwG0> MkDQNlM5PDRyM{i=
NCI-H661 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? MWG3NkBp MUTEUXNQ M2PzbGlEPTB;MUCg{txO M{Xhb|I{QDR2MEO4
NCI-H716 NGTld2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UNVAh|ryP MmeyO|IhcA>? MoDCSG1UVw>? NUP3elIzUUN3ME2xNEDPxE1? NWDOS5k2OjN6NESwN|g>
NCI-H1563 NX:yV|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn63NVAh|ryP NYnzVXNkPzJiaB?= NES3U5NFVVOR NVvHTYczUUN3ME2xNEDPxE1? Ml;ENlM5PDRyM{i=
NCI-H1792 NXzCS|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? MVm3NkBp MV;EUXNQ NHThW4lKSzVyPUGwJO69VQ>? NH;ORWEzOzh2NECzPC=>
NCI-H2030 NXjrdYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LNeFExKM7:TR?= M3zHPVczKGh? M1;PW2ROW09? MX;JR|UxRTFyIN88US=> M32wRVI{QDR2MEO4
NCI-H2052 NInETFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorjNVAh|ryP M{THOVczKGh? MYjEUXNQ NULzdItGUUN3ME2xNEDPxE1? M2\mc|I{QDR2MEO4
NCI-H2122 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfoRnBkOTBizszN MoLTO|IhcA>? MmLUSG1UVw>? NE[0bVFKSzVyPUGwJO69VQ>? NXn2W2hJOjN6NESwN|g>
NCI-H2228 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSNVAh|ryP NF3HUIM4OiCq MYjEUXNQ NXzaVpoxUUN3ME2xNEDPxE1? NWLZ[XRrOjN6NESwN|g>
OE-19 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf2V|UyOCEQvF2= M4L2ZlczKGh? NXrEWIVnTE2VTx?= NWTJ[VMxUUN3ME2xNEDPxE1? NV;F[mZQOjN6NESwN|g>
OE-21 M1fFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf5VHUyOCEQvF2= NWH3Z5dvPzJiaB?= M1HnNWROW09? MljETWM2OD1zMDFOwG0> M{LXWFI{QDR2MEO4
OE-33 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7sS3lNOTBizszN NX;Re|ZlPzJiaB?= Mo\wSG1UVw>? NUHSSHZtUUN3ME2xNEDPxE1? NUfIWHh[OjN6NESwN|g>
OVCAR-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLxd3cyOTBizszN MlzsO|IhcA>? NIWwfVBFVVOR NVrDPXl3UUN3ME2xNEDPxE1? MkX2NlM5PDRyM{i=
OVCAR-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TdZh{OTBizszN NIXyeIk4OiCq NH;n[GRFVVOR NX\2W3p6UUN3ME2xNEDPxE1? MUeyN|g1PDB|OB?=
OVCAR-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSzNVAh|ryP NYmzfId5PzJiaB?= Mmm0SG1UVw>? Ml7mTWM2OD1zMDFOwG0> NFHuOIgzOzh2NECzPC=>
P3HR-1 NUH4TYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP4ZYEyOCEQvF2= Mn71O|IhcA>? NEHkTG1FVVOR NXrMRlJrUUN3ME2xNEDPxE1? NXS0cGtjOjN6NESwN|g>
PC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnpNVAh|ryP NF7JTGQ4OiCq MX\EUXNQ MnG1TWM2OD1zMDFOwG0> NFq1fFEzOzh2NECzPC=>
Raji MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ixU|ExKM7:TR?= NUL1R5o4PzJiaB?= MYDEUXNQ M4S0WGlEPTB;MUCg{txO MkOxNlM5PDRyM{i=
RD MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTJVYVzOTBizszN NYfZdINMPzJiaB?= MUnEUXNQ MWjJR|UxRTFyIN88US=> MnjJNlM5PDRyM{i=
RD-ES NF75UmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK0[YQyOCEQvF2= NXX1OVE1PzJiaB?= NE\jOJRFVVOR MluwTWM2OD1zMDFOwG0> MkG3NlM5PDRyM{i=
RL NX[0fohsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfzWpBLOTBizszN M13Xd|czKGh? NXTyb5R[TE2VTx?= M2j4bWlEPTB;MUCg{txO MkX0NlM5PDRyM{i=
SaOS2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnSNVAh|ryP NV\MWXF[PzJiaB?= M1m1[GROW09? NXO1cVhGUUN3ME2xNEDPxE1? Ml3nNlM5PDRyM{i=
SCC-9 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1exR|ExKM7:TR?= MnPxO|IhcA>? M3W5b2ROW09? M4PhTGlEPTB;MUCg{txO MUWyN|g1PDB|OB?=
SCC-12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DCW|ExKM7:TR?= MYm3NkBp NEHpUndFVVOR NWXkSVJ1UUN3ME2xNEDPxE1? MoTkNlM5PDRyM{i=
SCC-13 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? NE\xOGk4OiCq M{nnSGROW09? NYi0WGtsUUN3ME2xNEDPxE1? MmfFNlM5PDRyM{i=
SCC-15 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrRNYVUOTBizszN MVi3NkBp M4Lxd2ROW09? M2rxcGlEPTB;MUCg{txO MVKyN|g1PDB|OB?=
SCC-25 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsN2MyOCEQvF2= MmizO|IhcA>? MV\EUXNQ NX\iPWNYUUN3ME2xNEDPxE1? NV3iRnREOjN6NESwN|g>
SCLC-3 NUDMdmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkNVAh|ryP MmPBO|IhcA>? NETJUlZFVVOR M2XpbmlEPTB;MUCg{txO NGi1OZUzOzh2NECzPC=>
SF-268 NV;YboJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3NVAh|ryP M4nKeFczKGh? Mkj1SG1UVw>? MXfJR|UxRTFyIN88US=> NEjM[HYzOzh2NECzPC=>
SF-295 NHHTZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPaOnkyOCEQvF2= MYe3NkBp NXvrVIhCTE2VTx?= MYrJR|UxRTFyIN88US=> NWXFZ|lnOjN6NESwN|g>
SJRH30 NW\jfWZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Wy[VExKM7:TR?= MkHFO|IhcA>? M{OzXWROW09? NUPCNox3UUN3ME2xNEDPxE1? NEGzT4UzOzh2NECzPC=>
SK-BR-3 NWnySGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3WeJZ7OTBizszN MmLRO|IhcA>? NGrQNVVFVVOR MWPJR|UxRTFyIN88US=> Ml;qNlM5PDRyM{i=
SK-LMS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvxUlAyOCEQvF2= MoHEO|IhcA>? MYHEUXNQ MU\JR|UxRTFyIN88US=> MViyN|g1PDB|OB?=
SK-N-DZ NEXOWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLJNVAh|ryP MVm3NkBp NHexRXFFVVOR MUPJR|UxRTFyIN88US=> NYfIUY1XOjN6NESwN|g>
SK-N-F1 NWHRPGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzSc|cyOTBizszN MYi3NkBp MlfaSG1UVw>? MkXkTWM2OD1zMDFOwG0> NVzBbmJvOjN6NESwN|g>
SKOV-3 NX\4UYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUNVAh|ryP NYDBclRTPzJiaB?= Mly5SG1UVw>? MVnJR|UxRTFyIN88US=> MkjlNlM5PDRyM{i=
SK-UT-1 NIW2V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGxNEDPxE1? NV\3RZBrPzJiaB?= M2T2XWROW09? NEfSPVNKSzVyPUGwJO69VQ>? NFHkUG4zOzh2NECzPC=>
SN12C MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxNEDPxE1? M{W0V|czKGh? NIn0cpZFVVOR MljwTWM2OD1zMDFOwG0> MUCyN|g1PDB|OB?=
SNB-19 M17KRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\UblIyOCEQvF2= NED4NlE4OiCq MV7EUXNQ MmnBTWM2OD1zMDFOwG0> MUmyN|g1PDB|OB?=
SNU-5 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e3OVExKM7:TR?= NX7QUlFyPzJiaB?= MVrEUXNQ M3fSWmlEPTB;MUCg{txO M{\ZeVI{QDR2MEO4
SNU-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17OdVExKM7:TR?= NHS2epA4OiCq M3zLdmROW09? M{LjSWlEPTB;MUCg{txO M3XZWFI{QDR2MEO4
SNU-398 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNEDPxE1? NWrLVmtHPzJiaB?= NYLrZYFCTE2VTx?= MVnJR|UxRTFyIN88US=> M4LtZ|I{QDR2MEO4
SNU-449 NYXYe245T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL6WnBQOTBizszN NFviO3I4OiCq MmfRSG1UVw>? NH7XN2hKSzVyPUGwJO69VQ>? NUKzcWhiOjN6NESwN|g>
SR M1PBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfOZlN4OTBizszN M1S3WlczKGh? NGOwOZZFVVOR NWHRTXRiUUN3ME2xNEDPxE1? MXWyN|g1PDB|OB?=
ST486 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxTm9YOTBizszN MUS3NkBp NGLJdVVFVVOR NVzpNnV2UUN3ME2xNEDPxE1? MkXVNlM5PDRyM{i=
SW579 M3XseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi4SIQyOCEQvF2= MoHzO|IhcA>? NIDhTFZFVVOR M{LzNGlEPTB;MUCg{txO MnPBNlM5PDRyM{i=
SW684 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlSwNVAh|ryP MVS3NkBp MmHaSG1UVw>? M1rTb2lEPTB;MUCg{txO NHXRdXAzOzh2NECzPC=>
SW-780 M{TzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK3U5UyOCEQvF2= MVm3NkBp MnPmSG1UVw>? NEG0V4NKSzVyPUGwJO69VQ>? MYKyN|g1PDB|OB?=
SW900 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HNNFExKM7:TR?= MYK3NkBp MlTISG1UVw>? M{jDN2lEPTB;MUCg{txO MXSyN|g1PDB|OB?=
SW1088 NXHkO2VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfhNVAh|ryP MoK2O|IhcA>? Mn22SG1UVw>? NVnCVZNiUUN3ME2xNEDPxE1? NYHtZZk1OjN6NESwN|g>
SW1463 NH7FRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxNEDPxE1? M3nZUlczKGh? MXrEUXNQ NVXhUmJGUUN3ME2xNEDPxE1? NGLsWXYzOzh2NECzPC=>
SW1990 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZ[lJvOTBizszN MXq3NkBp NFX3T4JFVVOR MnrITWM2OD1zMDFOwG0> NUnubpdCOjN6NESwN|g>
T47D MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknENVAh|ryP NWjxfIVUPzJiaB?= M1rPdGROW09? NWO0RYpFUUN3ME2xNEDPxE1? NIPrXlMzOzh2NECzPC=>
TE381.T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\McJoyOCEQvF2= MmfGO|IhcA>? NEPFR2VFVVOR NV\wOpQ4UUN3ME2xNEDPxE1? NYjCbFUzOjN6NESwN|g>
TK-10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XK[lExKM7:TR?= M4rrcFczKGh? MV\EUXNQ MU\JR|UxRTFyIN88US=> M2DsVlI{QDR2MEO4
U2OS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\YdVExKM7:TR?= NXL0WHQyPzJiaB?= NX7kdGZ{TE2VTx?= MXzJR|UxRTFyIN88US=> NY[1VWVwOjN6NESwN|g>
U251 M3TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xNEDPxE1? M{nFd|czKGh? NETBO3JFVVOR NVPEV|NtUUN3ME2xNEDPxE1? NEXLclkzOzh2NECzPC=>
UACC-812 NHrM[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zFVVExKM7:TR?= MY[3NkBp NILabpRFVVOR MXTJR|UxRTFyIN88US=> NXTJWI0zOjN6NESwN|g>
YAPC MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[5RlExKM7:TR?= NXfRb4tYPzJiaB?= NVPHW2tqTE2VTx?= M4HC[GlEPTB;MUCg{txO MnzYNlM5PDRyM{i=
ZR-75-1 NY\lNIhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW4VGpIOTBizszN MYW3NkBp M4q3PGROW09? NV\ueXM3UUN3ME2xNEDPxE1? MlzRNlM5PDRyM{i=
A375 M3TwbWZ2dmO2aX;uJIF{e2G7 NV\mPY5sOS5{IN88US=> NHzmO3Q1KGh? MlXTSG1UVw>? NIDvUohKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?= MoDCNlI{QDl2N{G=
YUSIT1 M320T2Z2dmO2aX;uJIF{e2G7 NHrsOmFFVVOR MXTy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0> MmDNNlI{QDl2N{G=
MeWo M{C4PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXLEUXNQ M{HBbmlEPTBiPTC5PFchdk1? NYLwXIs{OjZyMUi1NlQ>
WiDr M3zaVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrEUXNQ NFXGbFFKSzVyIE2gO|Yhdk1? NGexNo4zPjBzOEWyOC=>
Colo-205 M{nVbmZ2dmO2aX;uJIF{e2G7 NWK0cIl[OSEQvF2= NWjweJlvPCCm NUXFZnp3TE2VTx?= MX;JcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU> NHLDTYwzPTN6MUG1Ni=>
RBW-1 NECwd4hHfW6ldHnvckBie3OjeR?= MYCxJO69VQ>? MYjEUXNQ NY\1Wnh3Vm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w MX2yOFg5PTZ7MB?=
RBO-1 MV\GeY5kfGmxbjDhd5NigQ>? M2fGPVEh|ryP M2DxemROW09? Ml:zTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> MV6yOFg5PTZ7MB?=
RBO-2 NHPtZXRHfW6ldHnvckBie3OjeR?= Moi0NUDPxE1? MV\EUXNQ MVvJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=> MWCyOFg5PTZ7MB?=
RBOW NIrR[JpHfW6ldHnvckBie3OjeR?= M2jWO|Eh|ryP NIC2eZBFVVOR Mm\yTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NGnpcIUzPDh6NU[5NC=>
M257 NUPudnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HPNVExOCCwTR?= MXS3NkBp NFm0[4JFd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= M2XON|I{OzF5NES2
LCP MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP4NVAxKG6P NEPYOno4OiCq MXPJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u NFXvSJYzOzNzN{S0Oi=>
WM266 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\LfW0yODBibl2= MXm3NkBp Ml;4TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v NYfYS4w{OjN|MUe0OFY>
M257 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\VNVAxKG6P NITxbmc4OiCq NEnSRVVFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NYTae3RROjN|MUe0OFY>
LCP MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHeyRVMyODBibl2= M4\LPFczKGh? MoLZTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? MYiyN|MyPzR2Nh?=
WM266 NXHmPXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxNFAhdk1? M3PLWFczKGh? MlrZTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w NWP2RpBHOjN|MUe0OFY>

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03794297 Not yet recruiting BRAF NP_004324.2:p.V600X|Erdheim-Chester Disease National Cancer Institute (NCI) January 12 2020 Phase 2
NCT03794297 Not yet recruiting BRAF NP_004324.2:p.V600X|Erdheim-Chester Disease National Cancer Institute (NCI) January 12 2020 Phase 2
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03272464 Recruiting Melanoma Massachusetts General Hospital|Incyte Corporation November 30 2018 Phase 1
NCT03272464 Recruiting Melanoma Massachusetts General Hospital|Incyte Corporation November 30 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID